In nearly one-third of patients with Waldenstrom’s Macroglobulinemia, a specific genetic mutation switches on the disease, and a new drug that blocks the defective gene can arrest the disease in animal models, researchers at Dana-Farber Cancer Institute and allied institutions will report at the 2013 annual meeting of the American Society of Hematology.

See the article here:
New drug that blocks defective gene can arrest Waldenstrom’s Macroglobulinemia in animal models

Scroll to Top